Previously, we have shown that immunization with human papillomavirus (HPV) type 16‐
derived cytotoxic T lymphocyte (CTL) epitope E7 49–57 (RAHYNIVTF) renders C57BL/6 …

Cytotoxic T lymphocyte (CTL) peptide epitopes can be used for immunization of mice
against lethal virus infection. To study whether this approach can be successful against virus …

Previously, we identified human papillomavirus type 16 (HPV-16) E5 as a tumor rejection
antigen that can induce cytotoxic T lymphocytes (CTLs) to protect against tumor growth (DW …

In order to establish tumour-specific cytotoxic T lymphocyte (CTL) cell lines, T cells from a
human papillomavirus (HPV) type 16-positive patient with a cervical carcinoma in situ and …

Peptide-based vaccines aimed at the induction of effective T cell responses against
established cancers have so far only met with limited clinical success and clearly need to be …

Certain human papillomaviruses (HPV) have been implicated in the etiology of cervical
malignancies, and the E7 and E6 gene products of HPV type 16 are frequently expressed in …

Anchor residues in cytotoxic T-lymphocyte (CTL) epitope-bearing peptides are buried deep
in the major histocompatibility complex (MHC) class I antigen-presenting groove and are …

We analyzed capsomeres of human papillomavirus type 16 (HPV16) consisting of the L1
major structural protein for their ability to trigger a cytotoxic T-cell (CTL) response. To this …

Previously we have demonstrated that two doses of a cytotoxic T lymphocyte (CTL) epitope–
based peptide vaccine of human papillomavirus type 16 (HPV 16) E7 aa 49–57 elicit …

Abstract Human papillomavirus type 16 (HPV16) is strongly associated with cervical
carcinogenesis. The HPV16 E6 and E7 oncoproteins are constitutively expressed in the …